Gilead Sciences, Inc. (NASDAQ:GILD) Will Allow Generic Drugs Manufacturers To Make New Version Of Sovaldi

Gilead Sciences, Inc. (NASDAQ:GILD) was planning to launch its blockbuster hepatitis C drug Sovaldi in India by June, the company announced before US markets opened. The biotech firm also said that it aims to further the reach of its licensing…

Why Regeneron Closed Up Over 4% On Friday

Regeneron stock was up over 4% Friday, following the news that Regeneron’s PCSK9 inhibitor will be reviewed on Tuesday Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock shot up 4.01% Friday, as the company experimental drug – being developed in collaboration with Sanofi…

Sanofi SA Wins Breakthrough Therapy Designation For Novel Rare Disease Drug

Sanofi seems to be on track to gain the FDA’s approval for Olipudase Alfa after Genzyme’s success Sanofi SA’s (ADR) (NYSE:SNY) subsidiary Genzyme announced Thursday that its novel rare disease drug Olipudase Alfa has won breakthrough therapy designation from the…

Seattle Genetics (SGEN) Stock Up 3% After FDA Expanded The Approved Use of Adcetris

Seattle Genetics (SGEN) is up 3% in the last hour and 6% for the day after FDA today published a news release with keywords: “ADCETRIS PATIENTS REVIEW CHEMOTHERAPY APPROVAL CELL APPROVED LYMPHOMA AGENCY ONCOLOGY“. FDA expanded the approved use of Adcetris…

Pfizer Increased Prices in U.S. for More Than 100 Drugs

Pfizer Inc, which is planning a merger of $160 billion with Allergen based in Ireland to cut its annual tax bill, raised the prices in the U.S. on January 1 of over 100 drugs, of which some were hiked by…

Parent Company for Blue Cross Lost Over $1.5 Billion

The second year of the Affordable Care Act ended up being a big flop for the parent of Chicago based Blue Cross and Blue Shield but hints of a possible turnaround taking place. Health Care Service Corps’ losses in individual…

Becton Acquiring C.R. Bard in Deal Worth $24 Billion

Two of the largest suppliers in the healthcare industry in the world will become one as Becton, Dickinson & Co has agreed to acquire C.R. Bard Inc. at a price of $24 billion, which will create a huge powerhouse offering…

FDA Staff Supports Remicade Biosimilar

Staff members of the U.S. Food and Drug Administration said on Friday that Celltrion Inc’s biosimilar in form of Remicade an arthritis drug, which is made by Johnson & Johnson, appeared to be highly similar to the branded product. This…

StocksBeat

Democratizing access to all financial data. Cutting edge web platform for news and information.

Disclaimer: StocksBeat inform you that the data in this website is not necessarily real-time nor accurate. All prices are not provided by exchanges and prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Stocksbeat doesn`t bear any responsibility for any trading losses you might incur as a result of using the data.

Subscribe